Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07425028
Starting soon Observational

Evaluation of an Intensified Systematic Screening for Congenital Hypothyroidism in Premature Newborns

NCT07425028 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Lille
Phase
Observational
Started
2027-03
Last updated
2026-05-22

Condition(s) studied

Congenital Hypothyroidism

Investigational drug(s) / intervention(s)

Blood test →

Blood test: routine care blood draw

Study summary

Currently in France, screening for congenital hypothyroidism (CH) in premature infants is done by a single TSH assay on filter paper. However, European recommendations advise repeating the assay within the first month of life.

Our primary objective is to estimate the incidence of CH in preterm infants under 32 weeks of gestational age by applying the European recommendations.

Eligibility

Sex
ALL
Min age
23 Weeks
Max age
32 Weeks
Healthy volunteers
No
Inclusion Criteria: * Newborns born prematurely between 23 and 32 weeks of gestational age (up to 31 weeks and 6 days), both female and male, of all ethnic origins, regardless of birth weight, and including all other pathologies. * Newborns whose parents have given their non-opposition consent. Exclusion Criteria: * Newborns born who leave the region before day 15. * Newborns who die before 15 days of age. * Newborns whose parents are not affiliated with the social security system.

Primary outcome measure(s)

  • Annual incidence of congenital hypothyroidism among premature infants born before 32 weeks of gestational age — From birth to Day 15 of life
    The primary objective of the study is to estimate the annual incidence of congenital hypothyroidism among premature infants born before 32 weeks of gestational age, within 15 days of birth, by applying the European recommendations, which consist of performing two repeated tests within the first 15 days.

Trial sites (1)

FacilityCityRegionStatus
Chu de Lille Lille France

More University Hospital, Lille trials in France

Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation Recruiting
Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations Recruiting
Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease Recruiting
Lung Disease and FLNA Mutations Starting soon
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma Active, not recruiting

Other trials for the same condition

Prospective Evaluation of OptiThyDose Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07425028 on ClinicalTrials.gov ↗ ← All trials in France